Facebook
Twitter
Telegram
Report an ErrorEnlivex Therapeutics Ltd. Balance Sheet 2011-2024 | ENLV
Annual Balance Sheet Enlivex Therapeutics Ltd.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | - | -7.29 M | -10.6 M | -5.55 M | -146 K | - | ||
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
686 K | 4.19 M | 5.39 M | 499 K | 298 K | 198 K | - | - | 70 K | - | - | - | - |
Total Current Liabilities |
6.06 M | 6.61 M | 4.72 M | 4.37 M | 5.98 M | 1.13 M | 460 K | 1.93 M | 2.51 M | 2.28 M | - | - | - |
Total Liabilities |
6.75 M | 10.8 M | 10.1 M | 4.87 M | 6.28 M | 1.33 M | - | - | 2.58 M | 2.28 M | 131 K | 81 K | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-112 M | -83 M | -52 M | -37.5 M | -25.7 M | -16.3 M | -45.8 M | -39.8 M | -23.8 M | -8.42 M | -1.4 M | -229 K | - |
Total Assets |
36.8 M | 67.6 M | 95.1 M | 40.4 M | 17.6 M | 11 M | 3.62 M | 10.6 M | 20.5 M | 33 M | 5.69 M | 156 K | - |
Cash and Cash Equivalents |
- | - | - | 5.67 M | 3.95 M | 377 K | 3.53 M | 6.87 M | 262 K | 10.6 M | 270 K | 146 K | - |
Book Value |
30.1 M | 56.8 M | 85 M | 35.5 M | 11.3 M | 9.71 M | 3.62 M | 10.6 M | 17.9 M | 30.7 M | 5.56 M | 75 K | - |
Total Shareholders Equity |
30.1 M | 56.8 M | 85 M | 35.5 M | 11.3 M | 9.71 M | 8.49 M | 2.81 M | 5.46 M | 30.7 M | 175 K | 75 K | - |
All numbers in USD currency
Quarterly Balance Sheet Enlivex Therapeutics Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | 405 K | - | 499 K | - | 236 K | - | 298 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 5.39 M | - | 405 K | - | 499 K | - | 236 K | - | 298 K | - | - | - | 198 K | - | - | - | 351 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 10.1 M | - | 4.98 M | - | 4.87 M | - | 5.24 M | - | 6.28 M | - | - | - | 1.33 M | - | - | - | 1.05 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | -52 M | - | -43.8 M | - | -37.5 M | - | -29.5 M | - | -25.7 M | - | - | - | -16.3 M | - | - | - | -45.8 M | - | - | - | -39.8 M | - | - | - | -23.8 M | - | - | - | -8.42 M | - | - | - | -1.4 M | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 95.1 M | - | 95.2 M | - | 40.4 M | - | 35.4 M | - | 17.6 M | - | - | - | 11 M | - | - | - | 3.62 M | - | - | - | 10.6 M | - | - | - | 20.5 M | - | - | - | 33 M | - | - | - | 306 K | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 11.2 M | - | 12.6 M | 53.2 M | 5.67 M | - | 10.2 M | 24.8 M | 3.95 M | - | 16.1 M | - | 9.74 M | - | - | - | 9.03 M | - | - | - | 3.04 M | - | - | - | 7.29 M | - | - | - | 10.6 M | - | - | - | 270 K | - | - | - | 146 K | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 85 M | - | 90.2 M | - | 35.5 M | - | 30.2 M | - | 11.3 M | - | - | - | 9.71 M | - | - | - | 2.58 M | - | - | - | 10.6 M | - | - | - | 20.5 M | - | - | - | 33 M | - | - | - | 306 K | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 85 M | - | 90.2 M | - | 35.5 M | - | 30.2 M | - | 11.3 M | - | - | - | 9.71 M | - | - | - | 8.49 M | - | - | - | 2.81 M | - | - | - | 17.9 M | - | - | - | 30.7 M | - | - | - | 175 K | - | - | - | 75 K | - | - | - | - | - | - | - |
All numbers in USD currency